Entheon Biomedical
  • CSE:ENBI
  • OTC:ENTBF
  • ABOUT ENTHEON
  • REASONS TO BELIEVE
  • TEAM
  • INVESTORS
    • SHARE STRUCTURE
    • STOCK INFORMATION
    • FINANCIAL STATEMENTS
    • PRESS RELEASES & NEWS
  • CONTACT
Select Page
Interview with Timothy Ko, CEO, Entheon

Interview with Timothy Ko, CEO, Entheon

by Entheogen Biomedical | Jun 18, 2020 | Company News

Full interview available on psilocybinalpha.com
We can no longer ignore the potential of psychedelic drugs to treat depression

We can no longer ignore the potential of psychedelic drugs to treat depression

by Entheogen Biomedical | Jun 18, 2020 | Industry News

The world is experiencing a devastating physical health emergency. But the coronavirus pandemic has also seen a renewed focus on our psychological wellbeing. Loneliness, uncertainty and grief may be intensifying an already acute mental health crisis, and in the US...

Recent Posts

  • Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
  • Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial
  • Entheon Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
  • When Will Psychedelics be Legal in the United States?
  • MPV annonce l’approbation conditionnelle de sa transaction avec Entheon Biomedical Corp. par le CSE

Recent Comments

    Archives

    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020
    • April 2020
    • February 2020
    • December 2019
    • November 2019
    • July 2019
    • April 2019
    • December 2018
    • February 2018
    • January 2018

    Categories

    • Company News
    • Industry News
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Entheon Biomedical 2020 © All rights reserved | Website by S3 Communications | Terms & Privacy